| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3286196 | Clinics and Research in Hepatology and Gastroenterology | 2015 | 9 Pages |
SummaryBackground and aimIt has been shown that mean platelet volume (MPV) can be used as a prognostic biomarker in some chronic diseases. The aim of the present study is to investigate the possible association between MPV and clinical outcome and prognosis in patients with HBV-related acute-on-chronic liver failure (HBV-ACLF) within 4 weeks.MethodsThis study included 64 patients with HBV-ACLF, 19 chronic hepatitis B (CHB) patients, 27 patients with hepatitis B-related cirrhosis (CR, Child-Pugh A/B), 51 healthy subjects (healthy controls [HC]). The complete blood counts and biochemical examination of blood were obtained after 12 h of fasting. In the ACLF group, the relationships between the prognosis and the MPV were analyzed.ResultsAt baseline, a statistically significant increase in MPV was shown in patients with ACLF (median 9.5, range 7.1–14.1) compared with HC (8.0, 7.2–11.9, P < 0.001), CR (8.4, 5.9–11.1, P < 0.001) and CHB (8.3, 7.3–12.0, P < 0.001). The MPV value was positively correlated with model of end-stage liver disease (MELD) score and international normalized ratio (INR). The MPV level was significantly increased in nonsurvivors than survivors. High MPV level showed a significantly lower survival rate (P = 0.001). Multivariate logistic regression analysis showed that only MPV level was independent factor predicting poor short-term outcomes.ConclusionMPV values at presentation were higher among nonsurvivors than survivors, and this parameter was well correlated with liver function parameters and may be used as a predictor for 4-week mortality rate in patients with HBV-ACLF.
